Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
The trial investigates the use of KarXT XanomelineTrospium Chloride for preventing relapse in adults diagnosed with schizophrenia. Participants must have had schizophrenia for at least one year with recent hospitalization and persistent symptoms, evaluated by specific psychiatric scales. This Phase 3 randomized, double-blind, placebo-controlled study aims to assess how well KarXT maintains symptom control compared to placebo. Participants are randomly assigned to receive either KarXT or a placebo with specified doses given on set days. The study monitors participants over a period of up to approximately 43 weeks after randomization to evaluate relapse prevention. All treatments and follow-ups are masked to ensure unbiased assessment. During the study, participants undergo regular evaluations including psychiatric assessments using PANSS and CGI-S scores to measure symptom severity and relapse events. Safety is monitored through tracking of adverse events and special interest symptoms. The primary outcome measures the time from randomization to the first relapse. The total participation duration spans several months, with ongoing safety and efficacy assessments throughout the study period.
Actively Recruiting
Healthy Volunteer
Researchers are investigating the use of speech and self-report data to estimate relapse risk in people with psychotic disorders. This observational, multinational study involves individuals at risk of psychotic relapse and healthy controls, aiming to assess the feasibility of collecting speech data in six different languages over a 12-month period. The study explores new speech markers for predicting relapse while minimizing burden on participants and supports future research into clinical decision support systems. Participants will complete weekly speech assessments through a smartphone app, which collects speech and self-report data to be securely transferred for AI-based analysis. Two groups are involved individuals at risk of psychotic relapse and healthy controls. The study includes three in-person visits at baseline, six months, and twelve months to evaluate system usability and functional outcomes. Independent clinical evaluations ensure data quality and validate AI-generated risk scores, which are not shared with treating clinicians. During the study, participants will provide weekly speech recordings and self-reports, with quality control performed by designated reviewers checking audio and transcription accuracy. Researchers measure user adherence, transcription quality, usability of recordings, and the performance of the relapse prediction system. Follow-up assessments include clinical evaluations, functional and quality-of-life measures, and exploration of novel speech markers. The total participation lasts one year, with safety and usability monitored throughout.
Actively Recruiting
Researchers are evaluating the use of virtual reality exposure therapy VRET for treating obsessive-compulsive disorder OCD in inpatient adults aged 17 to 55. This randomized controlled trial compares three groups one receiving standard cognitive behavioral therapy CBT with VRET, another receiving CBT with VR cognitive training to improve cognitive flexibility, and a third group receiving standard CBT alone. The study aims to measure how well VRET works by assessing OCD symptoms and adherence to therapy assignments before and after treatment. The experimental group participates in a 6-week CBT program with five weekly 30-40 minute sessions using immersive VR glasses to experience scenarios in a virtual OCD house tailored to common OCD triggers like contamination, checking, and ordering. Therapists adjust difficulty levels and guide patients during sessions. The first control group receives the same CBT duration with VR games designed for cognitive training, while the second control group completes standard CBT without VR. All groups have regular group and individual psychotherapy sessions over the 6 weeks. Participants undergo repeated assessments using tools such as the Yale-Brown Obsessive-Compulsive Scale Y-BOCS, Beck Depression Inventory, and Beck Anxiety Inventory at baseline, during treatment, post-treatment, and 2 months after treatment ends. Adherence to exposure assignments and anxiety levels are also monitored. The study includes safety assessments for VR use and follows participants through a follow-up period to evaluate lasting effects.
Actively Recruiting
This research aims to evaluate the effectiveness of virtual reality exposure therapy VRET for treating obsessive-compulsive disorder OCD in outpatient psychiatry or clinical psychology settings. It uses a within-subject design where patients first undergo a waiting period before receiving treatment. The study focuses on patients diagnosed with OCD and assesses how well VRET works compared to a baseline waiting period. Participants start with informed consent and baseline questionnaires, followed by a five-week waitlist period without changing existing treatments. Afterward, they receive five weekly sessions of exposure therapy using virtual reality, involving immersive VR glasses and a virtual OCD house environment. The therapy targets common OCD triggers, including contamination, checking, ordering, and hoarding, with difficulty levels adjusted individually by therapists. Throughout the study, researchers monitor symptoms and treatment effects using several assessments, including the Yale-Brown Obsessive-Compulsive Scale, Beck Depression and Anxiety Inventories, and anxiety inventories before and after treatments and at 3-month follow-up. Therapy sessions are tracked for adherence and distress levels, with safety monitored via questionnaires after VR sessions. The total participation spans about ten weeks, covering waiting and treatment periods.